Two-Year Results for MC1273, a Phase 2 Evaluation of Aggressive Dose De- Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma (OPSCC)
Robert L. Foote(Mayo Clinic), Eric J. Moore(Mayo Clinic), Darlene E. Graner(Mayo Clinic in Arizona), Katharine A. Price(WinnMed), Samir H. Patel(WinnMed), Jeffrey R. Janus(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Jan L. Kasperbauer(Mayo Clinic), Ashish V. Chintakuntlawar(Mayo Clinic Hospital), Daniel L. Price(Mayo Clinic in Arizona), Yolanda I. Garces(Mayo Clinic), Javier García(Hospital General Yagüe), Nathan R. Foster(University Health Network), M.L. Hinni(WinnMed)
International Journal of Radiation Oncology*Biology*Physics
November 15, 2017
Cited by 16
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527